1 |
Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X. and Sun, D. : Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675 (2006).
DOI
ScienceOn
|
2 |
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. and Watkins, P. B. : Identification of rifampin-inducible P450IIIA4 (CYP2C9) in human small bowel enterocytes. J. Clin. Invest. 90, 1871 (1992).
DOI
|
3 |
Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L.Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998).
DOI
|
4 |
Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999).
DOI
ScienceOn
|
5 |
Reynolds, J. E. F. : Martindale - The Extra Pharmacopeia, Pharmaceutical Press. London (1993).
|
6 |
Kradjan, W. A., Takeuchi, K. Y., Opheim, K. E. and Wood, F. C. Jr. : Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy 15, 465 (1995).
|
7 |
Marchetti, P. and Navalesi, R. : Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin. Pharmacokinet. 16, 100 (1989).
DOI
ScienceOn
|
8 |
Marchetti, P., Giannarelli, R., di Carlo, A. and Navalesi, R. : Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clin. Pharmacokinet. 21, 308 (1991).
DOI
ScienceOn
|
9 |
Wahlin-Boll, E., Almer, L. O. and Melander, A. : Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin. Pharmacokinet. 7, 363 (1982).
DOI
ScienceOn
|
10 |
Zarghi, A., Foroutan, S. M., Shafaati, A. and Khoddam, A. : A rapid HPLC method for the determination of losartan in human plasma using a monolithic column. Arzneimittelforschung. 55, 569 (2005).
|
11 |
Kaminsky, L. S. and Fasco, M. J. : Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407 (1991).
|
12 |
Choi, D. H., Li, C. and Choi, J. S. : Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rat: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J. Pharm. Pharmacol. 62, 908 (2010)
DOI
|
13 |
Connacher, A. A., el Debani, A. H., Isles, T. E. and Stevenson, I. H. : Disposition and hypoglycaemic action of glipizide in diabetic patients given a single dose of nifedipine. Eur. J. Clin. Pharmacol. 33, 81 (1987).
DOI
ScienceOn
|
14 |
Niemi, M., Backman, J. T., Neuvonen, P. J. and Kivisro, K. T. : Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69, 400 (2001).
DOI
ScienceOn
|
15 |
Meadowcroft, A. M., Williamson, K. M., Patterson, J. H., Hinderliter, A. L. and Pieper, J. A. : The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 39, 418 (1999).
DOI
ScienceOn
|
16 |
Kaukonen, K. M., Olkkola, K. T. and Neuvonen, P. J. : Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. 53, 445 (1998).
|
17 |
Gan, L. S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3ALike cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug. Metab. Dispos. 24, 344 (1996).
|
18 |
McCrea, J. B., Cribb, A., Rushmore. T., Osborne, B., Gillen, L., Lo, M. W., Waldman, S., Bjornsson, T., Spielberg, S. and Goldberg, M. R. : Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin. Pharmacol. Ther. 65, 348 (1999).
DOI
ScienceOn
|
19 |
Wacher, V. J., Salphati, L. and Benet, L. Z. : Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug. Deliv. Rev. 46, 89 (2001).
DOI
ScienceOn
|
20 |
Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993).
DOI
ScienceOn
|
21 |
Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998).
DOI
|
22 |
Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999).
DOI
ScienceOn
|
23 |
Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993).
DOI
ScienceOn
|
24 |
Gan, L. S., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker, D.R. : CYP3ALike cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996).
|
25 |
Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996).
|
26 |
Lo, M. W., Goldberg, M. R., McCrea, J. B., Lu, H., Furtek, C. I. and Bjornsson, T. D. : Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP-3174 in humans. Clin. Pharmacol. Ther. 58, 641 (1995).
DOI
ScienceOn
|
27 |
Javier, D. : Review of the molecular pharmacology of losartan and its possiblerelevance to stroke prevention in patients with hypertension. Clinical. Therapeutics. 28, 832 (2006).
DOI
ScienceOn
|
28 |
McIntyre, M., Caffe, S. E., Michalak, R. A. and Reid, J. L. : Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol. Ther. 74, 181 (1997).
|
29 |
Inagami, T., Iwai, N., Sasaki, K., Yamamo, Y., Bardhan, S., Chaki, S., Guo, D. F. and Furuta. H. : Cloning, expression and regulation of angiotensin II receptors. J. Hypertens. 8, 713 (1992).
|
30 |
Soldner, A., Hildegard, S. L. and Mutschler, E. : HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP-3174 in biological material of humans and rats. J. Pharm. Biomed. Anal. 16, 863 (1998).
DOI
ScienceOn
|
31 |
Soldner, A., Christians, U., Susanto, M., Wacher, V. J., Silverman, J. A. and Benet, L. Z. : Grapefruit juice activates Pglycoprotein- mediated drug transport. Pharm. Res. 16, 478 (1999).
DOI
ScienceOn
|
32 |
Stearns, R. A., Chakravarty, P. K., Chen, R. and Chiu, S. H. : Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23, 207 (1995).
|
33 |
Stearns, R. A., Miller, R. R., Doss, G. A., Chakravarty, P. K., Rosegay, A., Gatto, G. J. and Chiu, S. H. : The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab. Dispos. 20, 281 (1992).
|
34 |
Yun, C. H., Lee, H. S., Lee, H., Rho, J. K., Jeong, H. G. and Guengerich, F. P. : Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug. Metab. Dispos. 23, 285 (1995).
|
35 |
Lewis, D. F. V. : Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, Function, and Mechanism. pp. 122-123. Taylor & Francis: Bristol. (1996).
|
36 |
Kradjan, W. A., Witt, D. M., Opheim, K. E. and Wood, F. C. Jr. : Lack of interaction between glipizide and co-trimoxazole. J. Clin. Pharmacol. 34, 997 (1994).
DOI
ScienceOn
|
37 |
Kivisto, K. T. and Neuvonen, P. J. : Enhancement of absortion and effect of glipizide by magnesium hydroxide. Clin. Pharmacol. Ther. 49, 39 (1991).
DOI
ScienceOn
|
38 |
Arauz-Pacheco, C., Ramirez, L. C., Rios, J. M. and Raskin, P. : Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin dependent diabetes recieving sulfonylurea therapy. Am. J. Med. 89, 811 (1990).
DOI
ScienceOn
|